Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Kate Skolnik, Paul Ronksley, Sachin R. Pendharkar, James P. Wick, Bradley S. Quon & Tyler Williamson. (2022) Hospital costs of Canadian cystic fibrosis patients. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 6:3, pages 145-152.
Read now
Read now
Articles from other publishers (14)
Aaron C Miller, Logan M Harris, Joseph E Cavanaugh, Mahmoud Abou Alaiwa, David A Stoltz, Douglas B Hornick & Philip M Polgreen. (2022) The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People With Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor. Clinical Infectious Diseases 75:7, pages 1115-1122.
Crossref
Crossref
Xiang Wang, Zuozhou Xie, Jinhong Zhao, Zhenghua Zhu, Chen Yang & Yi Liu. (2021) Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections. Frontiers in Cellular and Infection Microbiology 11.
Crossref
Crossref
Renee N. Ng, Anna S. Tai, Barbara J. Chang, Stephen M. Stick & Anthony Kicic. (2021) Overcoming Challenges to Make Bacteriophage Therapy Standard Clinical Treatment Practice for Cystic Fibrosis. Frontiers in Microbiology 11.
Crossref
Crossref
Patrick R. Secor, Elizabeth B. Burgener, M. Kinnersley, Laura K. Jennings, Valery Roman-Cruz, Medeea Popescu, Jonas D. Van Belleghem, Naomi Haddock, Conner Copeland, Lia A. Michaels, Christiaan R. de Vries, Qingquan Chen, Julie Pourtois, Travis J. Wheeler, Carlos E. Milla & Paul L. Bollyky. (2020) Pf Bacteriophage and Their Impact on Pseudomonas Virulence, Mammalian Immunity, and Chronic Infections. Frontiers in Immunology 11.
Crossref
Crossref
Maria Medina-Rojas, William Stribling, Erik Snesrud, Brittany I Garry, Yuanzhang Li, Patrick Mc Gann, Samandra T Demons, Stuart D Tyner, Daniel V Zurawski & Vlado Antonic. (2020)
Comparison of
Pseudomonas aeruginosa
strains reveals that Exolysin A toxin plays an additive role in virulence
. Pathogens and Disease 78:1.
Crossref
Crossref
G. Taccetti, M. Denton, K. Hayes, P. Drevinek, I. Sermet-Gaudelus, Diana Bilton, Silvia Campana, Daniela Dolce, Agnes Ferroni, Geneviève Héry-Arnaud, Marie-Teresa Martin-Gomez, Edward Nash, Luísa Pereira, Tanja Pressler & Burkhard Tümmler. (2020) A critical review of definitions used to describe Pseudomonas aeruginosa microbiological status in patients with cystic fibrosis for application in clinical trials. Journal of Cystic Fibrosis 19:1, pages 52-67.
Crossref
Crossref
Hoang D. Lu, Elizabeth Pearson, Kurt D. Ristroph, Gregg A. Duncan, Laura M. Ensign, Jung Soo Suk, Justin Hanes & Robert K. Prud'homme. (2018) Pseudomonas aeruginosa pyocyanin production reduced by quorum-sensing inhibiting nanocarriers. International Journal of Pharmaceutics 544:1, pages 75-82.
Crossref
Crossref
Stephanie Trend, Angela M. Fonceca, William G. Ditcham, Anthony Kicic & AREST CF. (2017) The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways. Journal of Cystic Fibrosis 16:6, pages 663-670.
Crossref
Crossref
Srilekha Panguluri, Praveen Gunda, Laurie Debonnett & Kamal Hamed. (2017) Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis. Clinical Drug Investigation 37:8, pages 795-805.
Crossref
Crossref
Ilene L. Hollin & Karen A. Robinson. (2015) A Scoping Review of Healthcare Costs for Patients with Cystic Fibrosis. Applied Health Economics and Health Policy 14:2, pages 151-159.
Crossref
Crossref
Michael S. Schechter, David Trueman, Rachel Farquharson, Keiko Higuchi & Cori L. Daines. (2015) Inhaled Aztreonam Lysine versus Inhaled Tobramycin in Cystic Fibrosis. An Economic Evaluation. Annals of the American Thoracic Society 12:7, pages 1030-1038.
Crossref
Crossref
Rafael Cantón, Luis Máiz, Amparo Escribano, Casilda Olveira, Antonio Oliver, Oscar Asensio, Silvia Gartner, Eva Roma, Esther Quintana-Gallego, Antonio Salcedo, Rosa Girón, María Isabel Barrio, María Dolores Pastor, Concepción Prados, María Teresa Martínez-Martínez, José Barberán, Juan José Castón, Luis Martínez-Martínez, José Luis Poveda, Carlos Vázquez, Javier de Gracia & Amparo Solé. (2015) Consenso español para la prevención y el tratamiento de la infección bronquial por Pseudomonas aeruginosa en el paciente con fibrosis quística. Archivos de Bronconeumología 51:3, pages 140-150.
Crossref
Crossref
Rafael Cantón, Luis Máiz, Amparo Escribano, Casilda Olveira, Antonio Oliver, Oscar Asensio, Silvia Gartner, Eva Roma, Esther Quintana-Gallego, Antonio Salcedo, Rosa Girón, María Isabel Barrio, María Dolores Pastor, Concepción Prados, María Teresa Martínez-Martínez, José Barberán, Juan José Castón, Luis Martínez-Martínez, José Luis Poveda, Carlos Vázquez, Javier de Gracia & Amparo Solé. (2015) Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients. Archivos de Bronconeumología (English Edition) 51:3, pages 140-150.
Crossref
Crossref
A. George F. Davidson, Mark A. Chilvers & Yolanda P. Lillquist. (2012) Effects of a Pseudomonas aeruginosa eradication policy in a cystic fibrosis clinic. Current Opinion in Pulmonary Medicine 18:6, pages 615-621.
Crossref
Crossref